CLINICAL_TRIALS trial_result · 2024-04-29

Clinical Trial Update: A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma [Phase 2]

A Phase 2 study evaluating IMM-101 in combination with checkpoint inhibitor therapy for advanced melanoma has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Immodulon Therapeutics Ltd | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-04-29